Invivyd (IVVD) Interest Expenses (2020 - 2026)
Invivyd's (IVVD) quarterly Interest Expenses came in at -$315000.0 in Q4 2025, up 55.26% YoY from -$202891.1 in Q4 2024, and down 138.27% on a QoQ basis from $823000.0 in Q3 2025.
Invivyd (IVVD) Interest Expenses (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has 6 years of Interest Expenses data on file, last reported at -$315000.0 in Q4 2025.
- Quarterly Interest Expenses rose 55.26% year-over-year to -$315000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$459000.0 (down 39.09% YoY) and the FY2025 annual result came in at $252.2 million, up 3.18% from the prior year.
- Interest Expenses eased to -$315000.0 in Q4 2025, from $823000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $586.8 million in Q3 2021 to a low of -$704000.0 in Q4 2024.
- A 5-year average of $36.3 million and a median of $435000.0 in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses soared 10494.0% — and 2023, when it tumbled 348.0%.
- Tracing IVVD's Interest Expenses over 5 years: stood at $200000.0 in 2021, then changed by 0.0% to $200000.0 in 2022, then sank by 348.0% to -$496000.0 in 2023, then sank by 41.94% to -$704000.0 in 2024, then jumped by 55.26% to -$315000.0 in 2025.
- The last three Interest Expenses figures came in at -$315000.0 (Q4 2025), $823000.0 (Q3 2025), and $360000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | 399,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 399,000.00 |
| Jun 30, 2026 | 399,000.00 |
| Dec 31, 2025 | -315,000.00 |
| Dec 31, 2025 | -315,000.00 |
| Sep 30, 2025 | 823,000.00 |
| Sep 30, 2025 | 823,000.00 |
| Jun 30, 2025 | 360,000.00 |
| Jun 30, 2025 | 360,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | -704,000.00 |
| Dec 31, 2024 | -704,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Jun 30, 2024 | 435,000.00 |
| Jun 30, 2024 | 435,000.00 |
| Mar 31, 2024 | 33.25 Mn |
| Mar 31, 2024 | 33.25 Mn |
| Dec 31, 2023 | -496,000.00 |
| Dec 31, 2023 | -496,000.00 |